Philips stock: Court rejects Respironics probe request

Philips received relief in one of the legal disputes linked to its Respironics recall after the Enterprise Chamber of the Amsterdam Court of Appeal rejected a shareholder request for an investigation. Ground News reported the ruling, issued on Saturday, October 10, 2026, citing coverage of the Dutch court decision.

The shareholders had alleged that Philips misled investors and that management failed to act appropriately over defective sleep apnea devices. The court found no indication that Philips knew about the defects before warnings were issued or that executives at the Respironics subsidiary should have intervened earlier.

Respironics case remains a risk

The ruling concerns the recall of roughly 15 million sleep apnea devices announced in 2021 after Philips found that foam in the machines could release harmful substances. Philips rejected the shareholders' accusations and welcomed the court's decision, according to the account reviewed by Ground News.

The decision removes one shareholder-led request for a deeper review of the company's conduct, but it does not resolve every legal issue connected with the recall. Philips still faces international legal pressure, including proceedings in France and claims related to personal injuries in the United States. For investors, the ruling narrows one avenue of scrutiny without eliminating the possibility of further costs, settlements or reputational damage.

Philips stock traded at 27.31 euros on Lang & Schwarz at 11:51 CET on Monday, November 9, 2026; the real-time quote of Philips stock is available here.

Investors can follow broader Dutch equity-market developments in the AEX market reports.

Further company developments and investor coverage are available in more news and analyses on Philips stock.